Seth Rudnick

Dr. Rudnick has extensive expertise in oncology, drug discovery and development, and healthcare investments. He is the Chairman of the Board of Directors of G1 Therapeutics, Inc. and is a member of its advisory board. Dr. Rudnick recently retired from Canaan Partners, where he built the global venture capital firm's capability in biopharmaceutical investing. Prior to joining Canaan, he was the CEO and Chairman of CytoTherapeutics, a developer of cell therapies to combat chronic diseases. He also helped start and led the development of Ortho Biotech, a division of Johnson & Johnson. Earlier in his career, Dr. Rudnick worked at Schering-Plough and directed pharmaceutical development efforts at Biogen. Dr. Rudnick was a Yale Fellow and Robert Wood Johnson scholar in medical oncology. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. He is a Clinical Professor of Medicine at the University of North Carolina at Chapel Hill, teaching and advising faculty members on biotechnology issues. He also currently serves as the Chairman of Liquidia Technologies and Meryx and a board member at Abyrx.